Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
In a Phase 2 obesity trial of retatrutide published in the New England Journal of Medicine in 2023, nausea, diarrhea, vomiting and constipation were cited as the most common adverse events, with higher doses associated with more severe problems
The STEP-1 trial (Wilding et al., New England Journal of Medicine , 2021) showed that patients who stopped at 1 mg lost an average of 10.9% body weight vs 15.8% at 2.4 mg
It displays both orexigenic and anabolic properties via ghrelin mimetic activity and transient increases in growth hormone (GH)
Visit our Wight Loss Treatment Plan page to review candidacy pricing and request your consultation.
Your body isnt fighting you
US$ 20.90
US$ 24.93
US$ 23.68
US$ 29.75
US$ 21.59
US$ 21.62
US$ 24.19
US$ 23.08
US$ 26.10
